|Bid||0.00 x 2900|
|Ask||0.00 x 1200|
|Day's range||40.18 - 40.66|
|52-week range||32.96 - 47.89|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||14.61|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||2.48 (6.12%)|
|Ex-dividend date||19 May 2022|
|1y target est||56.81|
PHILADELPHIA, August 08, 2022--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus
Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.
Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.